Table 2. Univariate Cox regression analyses of potential prognostic factors for overall survival and recurrence free survival in ccRCC patients.
| Variable | Overall survival | Recurrence free survival | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | |
| Tumor size: | 1.482 (1.368-1.605) | <0.001 | 1.510 (1.382-1.650) | <0.001 |
| Pathologic T stage: | ||||
| pT2 vs. pT1 | 4.060 (1.660-9.926) | 0.002 | 4.228 (1.597-11.196) | 0.004 |
| pT3 vs. pT1 | 5.219 (3.073-8.864) | <0.001 | 4.938 (2.775-8.786) | <0.001 |
| pT4 vs. pT1 | 11.796 (4.537-30.668) | <0.001 | 13.585 (5.170-35.696) | <0.001 |
| Pathologic N stage: | ||||
| pN1 vs. pN0 | 36.464 (15.261-87.125) | <0.001 | / | / |
| Pathologic M stage: | ||||
| pM1 vs. pM0 | 5.800 (1.815-18.536) | 0.003 | / | / |
| Fuhrman grade: | ||||
| 2 vs. 1 | 1.562 (0.528-4.616) | 0.442 | 1.387 (0.463-4.155) | 0.561 |
| 3 vs. 1 | 4.162 (1.422-12.183) | 0.010 | 3.584 (1.203-10.676) | 0.023 |
| 4 vs. 1 | 17.309 (6.049-49.528) | <0.001 | 15.008 (5.163-43.626) | <0.001 |
| Sarcomatoid change: | ||||
| Present vs. Absent | 19.680 (9.178-42.196) | <0.001 | 26.191 (10.910-62.878) | <0.001 |
| Rhabdoid appearance: | ||||
| Present vs. Absent | 9.308 (5.187-16.704) | <0.001 | 8.602 (4.419-16.745) | <0.001 |
| Coagulative necrosis: | ||||
| Present vs. Absent | 4.418 (2.734-7.140) | <0.001 | 3.967 (2.351-6.693) | <0.001 |
| LVI: | ||||
| Present vs. Absent | 4.501 (2.779-7.289) | <0.001 | 4.466 (2.651-7.525) | <0.001 |
| ECOG-PS: | ||||
| ≥1 vs. 0 | 5.004 (3.037-8.245) | <0.001 | 3.992 (2.270-7.020) | <0.001 |
| FUT3 expression: | ||||
| High vs. Low | 2.342 (1.436-3.821) | <0.001 | 2.076 (1.230-3.505) | 0.006 |
Abbreviations: ccRCC = clear cell renal cell carcinoma; FUT3 = Fucosyltransferase 3; LVI= lymphovascular invasion; ECOG-PS: Eastern Cooperative Oncology Group – Performance status.